What is the dosage of Eliquis (Apixaban) for stroke prophylaxis in nonvalvular atrial fibrillation?

Prepare for the PNN 7-Day Live Course Test with our comprehensive quiz. Enhance your skills with flashcards and multiple-choice questions, each with helpful hints and detailed explanations. Get ready to excel!

Multiple Choice

What is the dosage of Eliquis (Apixaban) for stroke prophylaxis in nonvalvular atrial fibrillation?

Explanation:
For stroke prophylaxis in nonvalvular atrial fibrillation, the standard dosage of Eliquis (Apixaban) is 5 mg taken orally twice a day (BID). This dosing regimen has been established based on clinical trials demonstrating its efficacy in reducing the risk of stroke in patients with this condition. The 5 mg dose reflects an appropriate balance between effectiveness and safety in a broad patient population. In some specific circumstances, such as when patients meet certain criteria (e.g., age, weight, or renal function), a reduced dose of 2.5 mg orally BID may also be considered. However, for the general dosing recommendation for stroke prevention in nonvalvular atrial fibrillation, the preferred dosage is clearly 5 mg BID. This ensures that patients receive an adequate anticoagulation effect to mitigate the risk of thromboembolic events associated with atrial fibrillation.

For stroke prophylaxis in nonvalvular atrial fibrillation, the standard dosage of Eliquis (Apixaban) is 5 mg taken orally twice a day (BID). This dosing regimen has been established based on clinical trials demonstrating its efficacy in reducing the risk of stroke in patients with this condition. The 5 mg dose reflects an appropriate balance between effectiveness and safety in a broad patient population.

In some specific circumstances, such as when patients meet certain criteria (e.g., age, weight, or renal function), a reduced dose of 2.5 mg orally BID may also be considered. However, for the general dosing recommendation for stroke prevention in nonvalvular atrial fibrillation, the preferred dosage is clearly 5 mg BID. This ensures that patients receive an adequate anticoagulation effect to mitigate the risk of thromboembolic events associated with atrial fibrillation.

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy